The IBD Registry is closing current activities by Easter 2024, and is in discussions through Spring 2024 about possible transition to an NHS organisation. See our Closure Announcement, Data Transfer Update, Closure FAQs and Achievements. 

Clinical KPIs for IBD

From IBD Audit to IBD Registry

In 2017, the national IBD Biological Therapies Audit officially transferred to the IBD Registry from the Royal College of Physicians (RCP). Following a transition period to become an independent not-for-profit company in 2017/18, the IBD Registry resumed publication of the annual Biological Therapies Report in 2019.

2023 Annual Report on Biological Therapy in IBD

The biological therapy review is a continuous programme of data collection to support clinical quality improvement in the treatment of patients with IBD in the UK. We analyse the data quarterly to provide IBD hospital teams with an ongoing review of clinical performance against the biological therapies KPIs (see top). In addition to this, our data analysis helps provide a picture of how the clinical management of biological therapies is changing on a national level.

Our 2023 annual report is available below:

 Annual Report on Biological Therapy in IBD 2023 (IBD Registry annual report, 2023). 

Reports and Publications

The following reports and papers are related to the biological therapies KPIs:

Annual Report on Biological Therapy in IBD 2022 (IBD Registry annual report, 2022).

Annual Report on Biological Therapy in IBD 2021 (IBD Registry annual report, 2021).

Audit of Biological Therapy for inflammatory bowel disease (Gut, 1 June 2019). 

Annual Report on Biological Therapy in IBD 2019 (IBD Registry annual report, 2019).